Menu
Recruiting NCT07391319

The Prospective, Double-blind, Multicenter, Placebo-controlled, Randomized, Comparative Clinical Trial

Phase III Interventional Ulcer Foot Mellitus Diabetes

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Neovasculgen®, Placebo.
Who it may be relevant to
Registry conditions: Ulcer Foot, Mellitus Diabetes. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Russia
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

"Prospective, Double-blind, Multicenter, Placebo-controlled, Randomized, Comparative Clinical Study of the Efficacy and Safety of the Drug Neovasculgen® Lyophilisate for the Preparation of a Solution for Intramuscular Administration 1.2 mg", Manufacturer Federal State Budgetary Institution "NMITs of Hematology" of the Ministry of Health of the Russian Federation, Russia in Patients With Diabetic Foot Syndrome"

Overview

The main objective of the study is to evaluate the efficacy and safety of Neovasculgen® in a course dose of 2.4 mg in combination with standard drug therapy in patients with unilateral neuroischemic form of diabetic foot syndrome.

Interventions

  • Drug Neovasculgen®
    The diluted drug will be administered by 5-10 injections intramuscularly twice with an interval of 14 days, in the course dosage mode - 2.4 mg
  • Drug Placebo
    Placebo will be administered by 5-10 injections intramuscularly twice with an interval of 14 days

Primary outcome measures

  • Number of participants who achieved complete healing of the ulcer defect through study completion, an average of 6 months [Time frame: Until the end of the study]
Secondary outcome measures (1)
  • Number of participants with partial ulcer defect healing through study completion, an average of 6 months [Time frame: Until the end of the study]

Eligibility criteria

Inclusion criteria

  • Male and female patients aged 18 years and above inclusive (at the time of study entry) with neuroischemic form of diabetic foot syndrome.
  • Type 1 or type 2 diabetes mellitus.
  • Prolonged non-healing ulcerative defect on the background of standard therapy (at least 1 month), limited to the foot.
  • Depth of ulcer defect according to Wagner Scale- 1 or 2 degrees.
  • Oxygen tension in the tissues directly adjacent to the ulcer defect area, from 20 to 45 mm Hg.
  • Patients with no urgent indications for limb amputation.
  • Acceptable ankle- brachial index range of 1.3-0.25.
  • Patient's willingness to comply with the requirements for examination and treatment.
  • Availability of written informed consent from the patient.
  • Patient's consent to follow the regimen of unloading the affected area throughout the study (for patients with plantar ulcer location)

Exclusion criteria

  • Age under 18.
  • Chronic ischemia of the lower limbs of non-atherosclerotic (other than diabetes mellitus) origin: vasculitis, systemic connective tissue diseases, Buerger's disease, congenital anomalies and vascular injuries, embolism.
  • Calcaneal localization of the ulcer.
  • Neuropathic form of diabetic foot syndrome.
  • Severe neuroosteoarthropathic deformity of the foot or other deformity that has a significant impact on the healing process.
  • Ischemia, threatening limb loss.
  • Presence of clinical signs of an infectious process in the ulcer area that is not controlled by the ongoing antibacterial therapy.
  • Presence of purulent-destructive lesions of the foot (abscess, phlegmon, osteomyelitis, etc.).
  • Skin changes associated with venous pathology.
  • Proliferative and terminal stages of diabetic retinopathy.
  • The level of glycated hemoglobin at the entrance to the study is more than 11%.
  • Diabetic ketoacidosis or diabetic precoma.
  • Systemic use of glucocorticosteroids and/or other immunosuppressive drugs within the last 30 days before inclusion in the study.
  • Recent (less than 1 month) surgery or endovascular intervention on the arteries of the lower extremities or recent (less than 1 month) deep vein thrombosis of the lower extremities.
  • Recent (less than 3 months) cases of acute myocardial infarction, unstable angina, coronary artery bypass grafting or stenting of the coronary arteries, stroke or transient ischemic attacks.
  • Planned major surgery in the next 6 months.
  • Severe concomitant disease with life expectancy less than one year.
  • Infectious diseases, septic conditions, HIV infection.
  • Diagnosis of cancer within the last 5 years.
  • Pregnancy, breastfeeding period.
  • Positive pregnancy test in women of reproductive age.
  • Alcohol or drug addiction.
  • Any other disease (including mental) or clinical condition that, in the opinion of the researcher, may affect the patient's ability to participate in the study.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Triple blind
Primary purpose
Treatment

Study locations

Russia · 1 center
  • Botkin Hospital — Moscow

Identifiers

NCT: NCT07391319 · FootDiabEndocrin-05-2024

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗